货号:A1340104
同义名:
SR 717 (lithium salt)
SR-717是一种非核苷类 STING 激动剂,其在 ISG-THP1 (WT) 和 ISG-THP1 cGAS KO(cGAS KO)细胞系中的 EC50 分别为 2.1 μM 和 2.2 μM,具有抗肿瘤活性。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 描述 | Stimulator of interferon genes (STING) is an endoplasmic reticulum signaling protein which has been demonstrated to play essential roles in antitumor immunity. SR-717 is a non-nucleotide, small-molecule STING agonist with an IC50 of 7.8 μM. Within the CD45.2+ population, SR-717 treatment resulted in a significant increase in the frequency of CD8 T cells among TILs (tumor infiltrating lymphocytes) and a decrease in the frequencies of NK cells within the draining lymphnode (dLN) and spleen. In WT C57BL/6 mice, SR-717 induced IFN-β after intraperitoneal administration in a dose-dependent manner. In WT or Stinggt/gt mice, a 30 mg/kg intraperitoneal once-per-day regimen of SR-717 for 1 week was found to maximally inhibit B16.F10 tumor growth. In C57BL/6 mice bearing B16.F10 cells, SR-717 (15 mg/kg; dosed intraperitoneally; once per day) significantly inhibited the formation of pulmonary nodules in this model of metastasis. SR-717 (30 mg/kg intraperitoneally) displayed a better level of efficacy than anti-PD-1 or anti-PD-L1 antibody therapy on reducing tumor burden and improving overall survival in the B16.F10 model[2]. |
| 作用机制 | The structure of SR-717 facilitates a binding mode in which Thr263 side chain hydroxyls from both monomers are positioned to form hydrogen-bond interactions with SR-717[2]. |
| Concentration | Treated Time | Description | References | |
| RAW264.7 cells | 10.0 µM | 24 hours | To assess the effect of SH-NPs on macrophage polarization, results showed that SH-NPs significantly reduced the expression of M2 macrophage marker CD206 and increased the expression of M1 macrophage marker CD86. | Pharmaceutics. 2024 Sep 17;16(9):1216. |
| DC2.4 cells | 10.0 µM | 24 hours | To evaluate the cellular uptake and STING pathway activation of SH-NPs, results showed that SH-NPs significantly increased the expression levels of p-TBK1 and p-IRF3 and enhanced IFN-β secretion. | Pharmaceutics. 2024 Sep 17;16(9):1216. |
| Administration | Dosage | Frequency | Description | References | ||
| Rats | Lung ischemia/reperfusion injury model | Intraperitoneal injection | 3 mg/kg | Single dose, 1 hour before surgery | Activation of STING aggravated endoplasmic reticulum stress (ERS), leading to increased apoptosis, inflammation, and oxidative stress, thereby exacerbating lung ischemia/reperfusion injury. | J Inflamm Res. 2022 Sep 5;15:5103-5119 |
| Mice | Periodontitis mouse model | Intraperitoneal injection | 30 mg/kg | Daily dosing for 7 days | SR-717-treated periodontitis mice displayed enhanced macrophage infiltration and M1 macrophage polarization in periodontal lesions compared with that in vehicle-treated periodontitis mice | Front Microbiol. 2023 Jun 19;14:1183415 |
| BALB/c mice | RENCA renal tumor model | Intravenous injection | 30.0 mg/kg | Single injection, observed for 16 days | To evaluate the tumor targeting and antitumor efficacy of SH-NPs, results showed that SH-NPs significantly enhanced drug accumulation in tumors and delayed tumor growth, with further improved therapeutic effects when combined with anti-PD-L1 antibody. | Pharmaceutics. 2024 Sep 17;16(9):1216. |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.85mL 0.57mL 0.28mL |
14.24mL 2.85mL 1.42mL |
28.47mL 5.69mL 2.85mL |
|
| CAS号 | 2375421-09-1 |
| 分子式 | C15H8F2LiN5O3 |
| 分子量 | 351.19 |
| SMILES Code | O=C([O-])C1=CC(F)=C(F)C=C1NC(C2=NN=C(N3C=CN=C3)C=C2)=O.[Li+] |
| MDL No. | N/A |
| 别名 | SR 717 (lithium salt) |
| 运输 | 蓝冰 |
| InChI Key | ODSAJRWPLSVEHJ-UHFFFAOYSA-M |
| Pubchem ID | 139434658 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry,2-8°C |
| 溶解方案 |
DMSO: 20 mg/mL(56.95 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1